IGF1R and ovarian cancer: Although therapeutic agents targeting the IGF1-R and small molecule tyrosine kinase inhibitors within the IGF signaling pathway have been investigated in the context of ovarian cancer, IGF-I/II monoclonal antibodies have not yet been explored.